Page 12 - Slide 1
P. 12
Amgen Bone Health Mentoring Program
Monday, October 15, at 11:30am – 2:30pm ◼ Ruth Chris, Minneapolis, MN
1173 Femur QCT Analysis using MIAF in
Postmenopausal Women Treated with Odanacatib -
Results of a 2-year Placebo-controlled Trial.
Engelke K, Fuerst T, Dardzinski B, et al.
Concurrent Oral Session 29: Osteoporosis - Treatment
(Clinical) ◼ Monday, October 15, 11:00 AM - 11:15 AM ◼
Auditorium-Main/Minneapolis Convention Center
Abstract Information Additional Notes from
Poster/Presentation*
Objective ▪ Using QCT, this study assessed the effects of
Methods ODN on femoral BMD in postmenopausal Strengths,
women Weaknesses, Key
Points
▪ This phase-3 trial included 214
postmenopausal women with mean BMD T-
scores of -1.8 at the lumbar spine and femoral
neck
▪ In this double-blind study, subjects were
randomized to receive ODN 50 mg weekly or
placebo; all participants received calcium and
vitamin D.
▪ QCT was used to assess BMD, BMC and
volume of the integral, cortical and trabecular
compartments
* Assignment notes will be collected at the Amgen Mentoring Program Debrief Meeting. Hardcopy or Electronic versions are acceptable
